Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant treatment after resection for patients with ALK-positive non-small cell lung cancer, as shown by an FDA-approved test, with tumors at least 4 cm or node positive.
LAMPGEN ANALYSIS
Why it matters
The ALK inhibitor moved from advanced disease into postoperative treatment for a defined group.
What research teams should watch
Retain the surgical pathology, ALK result and nodal assessment, and track two-year oral treatment exposure and interruptions.
PRIMARY RECORDS